Search
Results
newsFirst participants enrolled in PHOENIX trial
Amylyx Pharmaceuticals, Inc. today announced that the first participants have been dosed in their PHOENIX trial. This is a global study evaluating the safety and efficacy of the compound ‘AMX0035’ in people with ALS. The Phase 3 trial will be conducted at approximately 65 sites in Europe and the U.S. TRICALS is very...
ADORE trial enrolls first patient
The pharmaceutical company Ferrer has announced that the first patient has been enrolled in their ADORE (ALS Deceleration with ORal Edaravone) clinical trial. This Phase III trial will enrol about 300 patients across European countries. It will evaluate how effective and safe FNP122 (an oral formulation of edaravone...
CHU Lille
The SLA/ALS Reference Center and other Motor Neuron Rare Diseases coordinates the medical pathway of patients with rare diseases, from diagnosis to treatment.
centersCHU Gui de Chauliac, Montpellier
Our ALS center in Montpellier offers standard of care for patients with ALS or other motor neuron diseases. A multidisciplinary team is readily available to propose ttreatment options, preventive therapies, medical advice and to answer any questions regarding these diseases.
specialistsFlorence Esselin
Neurologist
specialistsOrla Hardiman
Consultant Neurologist, Head of the Academic Unit of Neurology
centersTrinity College Dublin
The National ALS service is co-located between the National Neuroscience Centre (Beaumont) and the Academic Unit of Neurology at Trinity College Dublin. The service provides multidisciplinary care to patients across Ireland, and engages in applied clinical research, along with Phase 1,2,3 and 4 clinical trials.
specialistsVeronique Danel Brunaud
Neurologist, Medical Coordinator of the ALS center
specialistsDavid Devon
Neurologist, Pharmacologist
specialistsBianca Broere
specialistsAndrea van Zijl
Research nurse
specialists